Previous 10 | Next 10 |
2024-03-12 14:15:03 ET JMP Securities analyst issues MARKET OUTPERFORM recommendation for OCUL on March 12, 2024 12:42PM ET. The previous analyst recommendation was Market Outperform. OCUL was trading at $9.145 at issue of the analyst recommendation. The overall analyst ...
2024-03-12 10:47:02 ET BTC iShares 20+ Year Treasury Bond ETF (TLT) TLT is trading DOWN for the last 4 days, and it at trading at $94.99 with volume of 7,676,393 and a one day change of $-0.69 (-0.72%). BTC iShares 20+ Year Treasury Bond ETF has a 52-week low of 82.42 and a 52-week ...
2024-03-11 16:46:57 ET Gainers: ESGEN Acquisition ( ESAC ) +40% . LifeMD ( LFMD ) +7% . Mission Produce ( AVO ) +4% . Flex ( FLEX ) +4% . Purple Innovation ( PRPL ) +3% . Losers: Power & Digital Infrastruc...
2024-03-11 16:10:21 ET More on Ocular Therapeutix Ocular Therapeutix: Diabetic Retinopathy Data Q2 2024 And Wet AMD Advancement Ocular Therapeutix Vies With Gene Therapies, Not Just Eylea, For Wet AMD Biggest stock movers today: EQT, MESO, Crypto-linked stocks, and m...
Leadership Appointments Move Ocular Towards Being a Leader in Retinal Care Screening Underway in AXPAXLI™ Phase 3 SOL-1 Trial for Wet AMD Topline Clinical Data for AXPAXLI in Diabetic Retinopathy and PAXTRAVA™ in Glaucoma Expected in Q2 2024 Cash Expected t...
Volcon Inc. (VLCN) is expected to report for Q4 2023 Tenaga Nasional Bhd ADR (TNABY) is expected to report for quarter end 2023-12-31 Hesai Group (HSAI) is expected to report for Q4 2023 Intrusion Inc. (INTZ) is expected to report $-0.14 for Q4 2023 Eliem Therapeutics Inc (ELYM) i...
2024-03-11 05:50:46 ET More on related stocks: Oracle Q3 Earnings Preview: Cloud Computing Business In Focus Blink Charging: EV Tailwinds Offer A Path To Profitability In 2025 Ulta Beauty: We Are Not Adding To Our Position Before The Earnings Release (Rating Downgrad...
2024-03-10 18:35:00 ET More on Ocular Therapeutix Ocular Therapeutix: Diabetic Retinopathy Data Q2 2024 And Wet AMD Advancement Ocular Therapeutix Vies With Gene Therapies, Not Just Eylea, For Wet AMD Ocular Therapeutix gains after $325M private placement Ocu...
BEDFORD, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for reti...
Crescent Energy Company Class A (CRGY) is expected to report $0.21 for Q4 2023 ThredUp Inc. (TDUP) is expected to report $-0.13 for Q4 2023 Wright Investors` Service Holdings Inc (IWSH) is expected to report for Q4 2023 Bridgford Foods Corporation (BRID) is expected to report for Q1 2...
News, Short Squeeze, Breakout and More Instantly...
Ocular Therapeutix Inc. Company Name:
OCUL Stock Symbol:
NASDAQ Market:
Ocular Therapeutix Inc. Website:
Recent Leadership Appointments Put Ocular on Track to Become a Leader in Retinal Care Site Activation and Patient Enrollment for AXPAXLI™ SOL-1 Phase 3 wet AMD Trial Progressing with First Subjects Randomized in April 2024 Cash Expected to Support Operations Into 2028, Ba...
BEDFORD, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) ("Ocular"), a biopharmaceutical company committed to enh...
BEDFORD, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related...